Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | FABP1 | P07148 | 1/20 | 0.52 |
| ▸ | FABP6 | P51161 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGAV | P06756 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6300353 | 0.98 | CYP1A2 (0.56) | CYP1A2CYP2C19HRH3CXCR4FABP1 | |
| SCHEMBL1831059 | 0.94 | CYP1A2 (0.56) | CYP1A2CYP2C19HRH3CXCR4FABP1 | |
| Hydrochloric Acid SCHEMBL6302628 | 0.93 | CYP1A2 (0.54) | CYP1A2CYP2C19HRH3CXCR4FABP1 | |
| SCHEMBL4715114 | 0.93 | CYP1A2 (0.54) | CYP1A2CYP2C19HRH3CXCR4FABP1 | |
| SCHEMBL10887684 | 0.93 | CYP1A2 (0.54) | CYP1A2CYP2C19HRH3CXCR4FABP1 | |
| SCHEMBL450877 | 0.88 | CYP1A2 (0.61) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| SCHEMBL10861718 | 0.88 | CYP1A2 (0.66) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| SCHEMBL3265804 | 0.88 | CYP1A2 (0.70) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| Hydrochloric Acid SCHEMBL7518301 | 0.86 | CYP1A2 (0.59) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| Hydrochloric Acid SCHEMBL5270311 | 0.86 | CYP1A2 (0.59) | CYP1A2CYP2C19CXCR4FABP1FABP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108521-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2026-04-23 | — | — | US | disclosed |
| WO-2025235957-A1 | P53 MUTANT STABILIZER AND USES THEREOF | FRONTIER MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4598918-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2025-08-13 | — | — | EP | disclosed |
| US-20250161307-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-22 | — | — | US | disclosed |
| US-20250017940-A1 | SELECTIVE PEPTIDOMIMETIC MODULATORS OF CAV2.2 (N-TYPE) VOLTAGE-GATED CALCIUM CHANNELS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4469454-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | Janssen Pharmaceutica NV (BE) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024073871-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024073871-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-04-11 | — | — | WO | disclosed |
| WO-2023141866-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | WO | disclosed |
| EP-3294732-B1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GILEAD SCIENCES INC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-4548940-A | Pyridylaminoalkylaminopyrimidones useful as histamine H1 -antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-10-22 | — | — | US | disclosed |
| US-4547506-A | 2-Pyridylaminoakylamino-4-pyrimidones useful as histamine H1 -antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-10-15 | — | — | US | disclosed |
| US-4532246-A | 2-(2-Pyridylaminoalkylamino)-4-pyrimidones | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-07-30 | — | — | US | disclosed |
| EP-0113572-A2 | Pyridine derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-07-18 | — | — | EP | disclosed |
| EP-0112707-A2 | Aminopyrimidinone derivatives as histamine H1-antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-07-04 | — | — | EP | disclosed |
| EP-0112704-A2 | Pyridine derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-07-04 | — | — | EP | disclosed |
| EP-0094595-A1 | Aziridine and phenylethanol amine derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-11-23 | — | — | EP | disclosed |
| US-4104382-A | (((THIAZOLYL-, ISOTHIAZOLYL- OR PYRIDYLALKYL)THIO)ALKYL)GUANIDINE | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-08-01 | — | — | US | disclosed |
| US-4018928-A | INHIBITORS OF H-2 HISTAMINE RECEPTORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-04-19 | — | — | US | disclosed |
| US-4000302-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108521-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | GHSR, GSPT1, GLRA1 | CYP1A2 759/4885CYP2C19 1298/4885HRH3 645/4885 |
| US-20250161307-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | SMOX, SRM, SMS | CYP1A2 423/4885CYP2C19 727/4885HRH3 458/4885 |
| US-20250017940-A1 | SELECTIVE PEPTIDOMIMETIC MODULATORS OF CAV2.2 (N-TYPE) VOLTAGE-GATED CALCIUM CHANNELS AND USES THEREOF | CACNA1B, CACNA1E, CACNA1D | CYP1A2 3325/4885CYP2C19 4601/4885HRH3 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.